ConductScience.org, home

Paper39655198

Targeted lung cancer screening in the age of immunotherapies and targeted therapies - an economic evaluation for Australia.

Roseleur J and 7 others. Lancet Reg Health West Pac, 2024. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Targeted lung cancer screening in the age of immunotherapies and targeted therapies - an economic evaluation for Australia. Papers, record 39655198. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39655198

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Targeted lung cancer screening in the age of immunotherapies and targeted therapies - an economic evaluation for Australia.
PubMed
Journal
Lancet Reg Health West Pac
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
0.91, provisional
iCite
Revised in PubMed
2024-12-11
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Roseleur JJacqueline
2Karnon JJonathan
3de Koning HHarry
4Milch VVivienne
5Anderson KKatrina
6Real JJacqui
7Keefe DDorothy
8Ten Haaf KKevin

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References41

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
132786189The Effect of Advances in Lung-Cancer Treatment on Population Mortality.N Engl J Med2020https://conductscience.org/library/papers/32786189PubMed
228376113Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.PLoS Med2017https://conductscience.org/library/papers/28376113PubMed
333687470Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement.JAMA2021https://conductscience.org/library/papers/33687470PubMed
431995683Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial.N Engl J Med2020https://conductscience.org/library/papers/31995683PubMed
532866213Health services costs for lung cancer care in Australia: Estimates from the 45 and Up Study.PLoS One2020https://conductscience.org/library/papers/32866213PubMed
633687469Evaluation of the Benefits and Harms of Lung Cancer Screening With Low-Dose Computed Tomography: Modeling Study for the US Preventive Services Task Force.JAMA2021https://conductscience.org/library/papers/33687469PubMed
737883107Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US.JAMA Oncol2023https://conductscience.org/library/papers/37883107PubMed
837357233Development and Validation of txSim: A Model of Advanced Lung Cancer Treatment in Australia.Pharmacoeconomics2023https://conductscience.org/library/papers/37357233PubMed
929377878Implementing Endobronchial Ultrasound-Guided (EBUS) for Staging and Diagnosis of Lung Cancer: A Cost Analysis.Med Sci Monit2018https://conductscience.org/library/papers/29377878PubMed
1022882884Chapter 2: Birth-cohort-specific estimates of smoking behaviors for the U.S. population.Risk Anal2012https://conductscience.org/library/papers/22882884PubMed
1136592498Economic impact of using risk models for eligibility selection to the International lung screening Trial.Lung Cancer2023https://conductscience.org/library/papers/36592498PubMed
1221714641Reduced lung-cancer mortality with low-dose computed tomographic screening.N Engl J Med2011https://conductscience.org/library/papers/21714641PubMed
1336745885Risk Model-Based Lung Cancer Screening : A Cost-Effectiveness Analysis.Ann Intern Med2023https://conductscience.org/library/papers/36745885PubMed
1436323879Updated cost-effectiveness analysis of lung cancer screening for Australia, capturing differences in the health economic impact of NELSON and NLST outcomes.Br J Cancer2023https://conductscience.org/library/papers/36323879PubMed
1525312998Lung cancer detectability by test, histology, stage, and gender: estimates from the NLST and the PLCO trials.Cancer Epidemiol Biomarkers Prev2015https://conductscience.org/library/papers/25312998PubMed
1631246249Evaluation of USPSTF Lung Cancer Screening Guidelines Among African American Adult Smokers.JAMA Oncol2019https://conductscience.org/library/papers/31246249PubMed
1732040195Disparities of National Lung Cancer Screening Guidelines in the US Population.J Natl Cancer Inst2020https://conductscience.org/library/papers/32040195PubMed
1831566216A Comparative Modeling Analysis of Risk-Based Lung Cancer Screening Strategies.J Natl Cancer Inst2020https://conductscience.org/library/papers/31566216PubMed
1937792671Cost-effectiveness of risk-based low-dose computed tomography screening for lung cancer in Switzerland.Int J Cancer2024https://conductscience.org/library/papers/37792671PubMed
2023425165Selection criteria for lung-cancer screening.N Engl J Med2013https://conductscience.org/library/papers/23425165PubMed

See all 41 referencesDownload CSV of references

Cited by6

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
42549076Use and impact of risk-based eligibility models in low-dose computed tomography lung cancer screening: a systematic review.Public Health Rev2026https://conductscience.org/library/papers/42549076PubMed
42487098Cost-Effectiveness and Budget Impact of Lung Cancer Screening: A Systematic Review.Pharmacoeconomics2026https://conductscience.org/library/papers/42487098PubMed
41277588Impact of lung cancer screening eligibility criteria on participants' characteristics and healthcare resources.Int J Cancer2026https://conductscience.org/library/papers/41277588PubMed
40932847Influence of changing patterns in lung cancer treatment and survival on the cost-effectiveness of CT screening: a modeling study.EClinicalMedicine2025https://conductscience.org/library/papers/40932847PubMed
40705331Computed Tomographic Screening Intervals for Patients at Moderate Risk of Lung Cancer.JAMA Netw Open2025https://conductscience.org/library/papers/40705331PubMed
40387288'Every Touch Point Is an Opportunity': Tobacco Control Experts' Views on How to Implement Smoking Cessation Interventions Within an Australian Lung Cancer Screening Program.Cancer Med2025https://conductscience.org/library/papers/40387288PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39655198

GET https://conductscience.org/api/papers/v1/39655198/references?page=2